Application of a Novel CD206+ Macrophage-Specific Arterial Imaging Strategy in HIV-Infected Individuals.

Lauren Stone, Steven K Grinspoon, Georges El-Fakhri, Kenneth C Williams, Udo Hoffmann, Thomas Brady, Bonnie Abbruzzese, Fred Cope, Amanda Martin, Markella V Zanni, Borek Foldyna, Patrick Autissier, Joshua Walker, Tricia H Burdo, Michael T Lu, Moses Q Wilks, Mabel Toribio

Journal: The Journal of infectious diseases 2017;215(8):1264-1269

PMID: 28204544

Abstract

BACKGROUND

The ability to noninvasively assess arterial CD206+ macrophages may lead to improved understanding of human immunodeficiency virus (HIV)-associated cardiovascular disease.

METHODS

We trialed a novel macrophage-specific arterial imaging technique.

RESULTS

We demonstrated colocalization between technetium Tc 99m tilmanocept (99mTc-tilmanocept) and CD206+ macrophages ex vivo. In vivo application of 99mTc-tilmanocept single-photon emission computed tomography/computed tomography revealed high-level 99mTc-tilmanocept uptake across 20.4% of the aortic surface volume among HIV-infected subjects, compared with 4.3% among non-HIV-infected subjects (P = .009). Among all subjects, aortic high-level 99mTc-tilmanocept uptake was related to noncalcified aortic plaque volume (r = 0.87; P = .003) on computed tomographic angiography, and this relationship held when we controlled for HIV status.

CONCLUSION

These first-in-human data introduce a novel macrophage-specific arterial imaging technique in HIV.

CLINICAL TRIALS REGISTRATION

NCT02542371.

© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: [email protected].

Address: Program in Nutritional Metabolism and.; Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston.; Cardiac MR PET CT Program, and.; Biology Department, Boston College, Chestnut Hill, Massachusetts.; Navidea Biopharmaceuticals, Dublin, Ohio.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.